Van­da takes is­sue with FDA's re­lay of de­fi­cien­cies for new Het­lioz in­di­ca­tion

Van­da Phar­ma­ceu­ti­cals said on Mon­day that the FDA no­ti­fied the com­pa­ny of sev­er­al de­fi­cien­cies in the sup­ple­men­tal new drug ap­pli­ca­tion for its in­som­nia med­ica­tion Het­lioz, which means the agency can­not ap­prove the drug im­me­di­ate­ly.

The new in­di­ca­tion for Het­lioz — to treat in­som­nia char­ac­ter­ized by dif­fi­cul­ties with sleep ini­ti­a­tion — ran in­to a road­block, but Van­da said that the FDA did not dis­close any de­fi­cien­cies to the com­pa­ny and this is not a for­mal de­ci­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER